Positive surgical margin after attempted radical surgery in patients with locally advanced urothelial carcinoma: literature review and case reports

Author:

Volkova М. I.1ORCID,Gridneva Ya. V.2ORCID,Al-Akel I. S.3ORCID,Ryabinin R. I.3

Affiliation:

1. Oncology Center No. 1 of the City Clinical Hospital named after S. S. Yudin of the Moscow Department of Health; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia

2. Oncology Center No. 1 of the City Clinical Hospital named after S. S. Yudin of the Moscow Department of Health; I. M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

3. Oncology Center No. 1 of the City Clinical Hospital named after S. S. Yudin of the Moscow Department of Health

Abstract

   Positive surgical margin is observed in approximately 10 % of specimens after radical surgery for locally advanced urothelial carcinoma, and is associated with an increased risk of locoregional recurrence, metastases, and death. R+ patients are a heterogeneous group of patients requiring individual treatment approaches. There is no standard of care for R+ patients; acceptable options include observation, removal of residual tumor, postoperative chemotherapy (CT), immunotherapy (IT), radiation therapy (RT), and chemoradiotherapy (CRT). The choice of treatment plan depends on the location and characteristics of the primary tumor, use of neoadjuvant chemotherapy (NACT) before surgery and the response to it, the pathological response, the presence of detectable residual tumor, as well as the potential tolerability of immediate postoperative treatment.

Publisher

Russian Society of Clinical Oncology

Reference23 articles.

1. Gladkov O.A., Bulychkin P.V., Volkova M.I. et. al. Practical recommendations for drug treatment of bladder cancer. Zlokachestvennie opuholi = Malignant Tumors 2023;13(3s2):620–639. doi: 10.18027/2224-5057-2023-13-3s2-1-620-639. (In Russ.)

2. Clinical Guidelines. Bladder Cancer, 2023. Available at: https://cr.minzdrav.gov.ru/schema/11_3. (In Russ.)

3. Bajorin D.F., Witjes J.A., Gschwend J.E. et.al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med 2021;384(22):2102–2114. doi: 10.1056/NEJMoa2034442.

4. Leaflet - information for the patient Opdivo, 10 mg/kg. Available at: https://grls.rosminzdrav.ru/InstrImg/2023/05/16/1493561/173eab27-c014-41e6-bd7b-a165ca84aac3.pdf

5. Clinical Guidelines. Urothelial cancer of the upper urinary tract, 2023. Available at: https://oncology-association.ru/wp-content/uploads/2023/11/urotelialnyj_rak_verhnih_moch_putej_23.pdf?ysclid=lywpj4ujz8771414912. (In Russ.)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3